Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 19;11(2):344. doi: 10.3390/diagnostics11020344

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Progression-free survival (PFS) subgroup analysis of key Hippo signaling genes for OC patients, according to high or low expression level based on TP53 status. PFS analysis of key Hippo signaling genes (MST1, LATS1, LATS2, TAZ, MST1, and TEF) for OC patients separated on TP53 status. PFS survival curve of OC patients according to the expression of Kaplan–Meier plotter (https://kmplot.com/analysis/index.php?p=service, accessed on 4 January 2021) based on TCGA patients, a log-rank test was used for TP53 mutated and TP53 wild-type (LATS1 high/low, wild-type TP53 p = 0.32 and mutant TP53 p = 0.093; TP53 high/low, wild-type TP53 p = 0.03 and mutant TP53 p = 0.012; LATS2 high/low, wild-type TP53 p = 0.0091 and mutant TP53 p = 0.0067; TAZ high/low, wild-type TP53 p = 0.26 and mutant TP53 p = 0.89; MST1 high/low, wild-type TP53 p = 0.11 and mutant TP53 p = 0.69; TEF high/low, wild-type TP53 p = 0.047 and mutant TP53 p = 0.015).